BridgeBio Pharma (BBIO) Income from Non-Controlling Interests (2018 - 2026)

BridgeBio Pharma has reported Income from Non-Controlling Interests for 9 years, with the latest figure at -$2.5 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 14.91% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (up 5.6% YoY) and the FY2025 annual result came in at -$8.0 million, down 5.56% from the prior year.
• Income from Non-Controlling Interests retreated to -$2.5 million in Q1 2026 per BBIO's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $7.3 million in Q2 2022 and troughed at -$4.9 million in Q1 2022.
• A 5-year average of -$1.9 million and a median of -$2.2 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests surged 227.44% in 2022, then slumped 138.43% in 2023.
• Over 5 years, Income from Non-Controlling Interests stood at -$3.0 million in 2022, then rose by 26.82% to -$2.2 million in 2023, then retreated by 7.29% to -$2.3 million in 2024, then climbed by 24.24% to -$1.8 million in 2025, then sank by 41.76% to -$2.5 million in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$2.5 million, -$1.8 million, and -$2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.